NetApp Teams with VMware, AWS to Help Customers Modernize and Scale Enterprise Workloads on the Cloud

15.9.2022 04:31:00 EEST | Business Wire | Press release

NetApp® (NASDAQ: NTAP), a global, cloud-led, data-centric software company, in collaboration with VMware, Inc. and Amazon Web Services (AWS), today announced the general availability of Amazon FSx for NetApp ONTAP with VMware Cloud on AWS, the first and only native AWS cloud storage service certified and supported as a supplemental datastore for VMware Cloud on AWS.

With this new datastore solution, enterprises can quickly, easily and cost-effectively move their enterprise, data-demanding workloads to VMware Cloud on AWS. This allows organizations to scale cloud storage independent of cloud compute to optimize costs, deploy new modern applications with the speed and scalability of the cloud, and maximize the value of their existing IT investments. Additionally, organizations can gain access to the rich data management, protection, and efficiency benefits of ONTAP utilized by nearly twenty thousand VMware customers running on-premises today.

“Our strong relationship, deep integration and joint innovation with both VMware and AWS hits another milestone, which helps make it easier for organizations to efficiently move enterprise workloads to the cloud,” said Phil Brotherton, Vice President, Solutions & Alliances at NetApp. “VMware customers running on NetApp or non-NetApp storage onpremises can now access the enterprise-class public cloud storage services and features of ONTAP, all running on AWS, as the first certified and supported supplemental datastore to VMware Cloud on AWS.”

“The majority of enterprises today run workloads on a VMware platform. Whether that is on premises or in VMware Cloud on AWS, they want to be able to leverage consistency in operations and architecture,” said Narayan Bharadwaj, Vice President, Cloud Solutions at VMware. “AWS, NetApp and VMware are giving customers the flexibility to buy and configure cloud storage independent of compute to meet the needs of a wide variety of enterprise applications. Our co-innovation will enable customers moving enterprise workloads to the cloud to cost-optimize and better scale their environments.”

New benefits from this certified and supported offering include improved:

Speed: Migrate data-demanding on-premises vSphere-based workloads with NetApp or non-NetApp storage to VMware Cloud on AWS with reduced complexity – leveraging consistent VMware-to-VMware migration for workloads combined with the speed, performance and simplicity of ONTAP via Amazon FSx for NetApp ONTAP.
Cost Control: Scale VMware Cloud compute independent of cloud storage to optimize cost at scale for demanding workloads combined with the rich data efficiency features of ONTAP to control cost at scale, including dedupe, compression, compaction, and thin provisioning.
Efficiency: Leverage existing VMware-centric resource investments including people, processes and technologies from on-premises and on the cloud for consistency of operations.

In addition, partners of NetApp, VMware and AWS can benefit from this innovation to expand their current offerings around VMware Cloud in multiple ways:

Unlock new business for hybrid and cloud-native workloads through breaking down cost barriers to migrating enterprise workloads through right-sizing cloud compute and cloud storage.
Expand existing cloud services helping customers plan, design, deploy and optimize enterprise hybrid and cloud-native solutions for data-demanding workloads.
Reduce risk for their clients through integrated and supported cloud solutions from NetApp and VMware to help customers migrate, extend or protect enterprise workloads to the cloud with confidence.

“As a leading multi-brand provider of full stack IT solutions, our customers rely on us to deliver solutions and services to help them manage their most data-demanding workloads,” said Troy Brick-Margelofsky, Digital Infrastructure Team Lead at CDW. “With Amazon FSx for NetApp ONTAP as a certified and supported datastore for VMware Cloud, we can now help customers move workloads on to the cloud quickly and efficiently, saving them time, money, and resources with the added benefit of integration with the complete NetApp portfolio.”

Amazon FSx for NetApp ONTAP provides fully managed shared storage on AWS with the popular data access and management capabilities of ONTAP. The solution allows organizations to easily migrate applications and run them on AWS, with ONTAP’s enterprise-grade storage workflows and data management capabilities, regardless of their on-premises storage provider.

Amazon FSx for NetApp ONTAP supplemental datastore for VMware Cloud on AWS is available today.

Additional Resources

About NetApp

NetApp is a global, cloud-led, data-centric software company that empowers organizations to lead with data in the age of accelerated digital transformation. The company provides systems, software and cloud services that enable them to run their applications optimally from data center to cloud, whether they are developing in the cloud, moving to the cloud, or creating their own cloudlike experiences on premises. With solutions that perform across diverse environments, NetApp helps organizations build their own data fabric and securely deliver the right data, services, and applications to the right people—anytime, anywhere. Learn more at www.netapp.com or follow us on Twitter, LinkedIn, Facebook, and Instagram.

NETAPP, the NETAPP logo, and the marks listed at www.netapp.com/TM are trademarks of NetApp, Inc. Other company and product names may be trademarks of their respective owners.

VMware and vSphere are registered trademarks or trademarks of VMware, Inc. or its subsidiaries in the United States and other jurisdictions.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220830005373/en/

Contact information

Media Contact:
Kenya Hayes
NetApp
kenya.hayes@netapp.com

Investor Contact:
Lance Berger
NetApp
lance.berger@netapp.com

About Business Wire

Business Wire

http://www.businesswire.com

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Biocytogen Grants Taisho Pharmaceutical a License to its RenNano ® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 14:00:00 EEST | Press release

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro

Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 14:00:00 EEST | Press release

Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a

Samsung Biologics Strike: Labor Union Warns of CDMO Supply Chain Risks Following Overwhelming Vote30.3.2026 12:52:00 EEST | Press release

The Samsung Biologics Labor Union (President: Jaesung Park), representing approximately 75% of the company's total employees, announced today that its members have overwhelmingly voted in favor of a strike, with 95.52% voting in favor on a 95.38% turnout during a voting period from March 24 to March 29. Following the Incheon Regional Labor Relations Commission's decision to cease mediation, the union has now secured the legal mandate to strike. The union stressed that this strike is not merely a wage dispute. It stems from deep structural concerns regarding the company’s ESG management, lack of operational autonomy, and passive labor relations. Primarily, the union highlighted unresolved corporate governance issues, including allegations concerning unfair labor practices and the unauthorized use of employee personal data, which were prominently reported by South Korea's major broadcaster, MBC, in November 2025. The union believes this crisis stems from management's failure to address r

The Premier Jumping League (PJL) Launches with a Record-Breaking $300 Million Guaranteed Prize Pot, Defining a New Era for Showjumping30.3.2026 12:00:00 EEST | Press release

The Premier Jumping League (PJL) launches with a record-breaking $300 million guaranteed prize pot, defining a new era for showjumping. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330990938/en/ Photography credits: Daniel Benson for The Premier Jumping League/ Wieden+Kennedy London Backed by McCourt Global and its Executive Chairman, Frank McCourt, the PJL is a groundbreaking global competition that elevates high-performance riders and horses to their rightful place on the world stage. Built on merit, integrity, and excellence, the PJL brings together the world’s best athletes to compete for the biggest prize pot in the discipline’s history, helping to create a more resilient, long-term financial model for the sport. Represented by sixteen teams, the PJL will introduce an industry-first rider selection process from a pool of 250 of the world’s leading riders. World-class, immersive events will unfold across fourteen ic

Dompé Announces First Patient Enrolled in New Study of Intranasal NGF in Cerebral Palsy30.3.2026 12:00:00 EEST | Press release

Dompé, a leading biopharmaceutical company with operations in Italy and in the U.S., announced that the first patient has been enrolled at the Agostino Gemelli IRCCS University Hospital in Rome, Italy, in a Phase 2 investigational study of an intranasal form of Nerve Growth Factor (NGF) (Cenegermin-bkbj) for the treatment of spastic cerebral palsy (CP). On top of safety and tolerability, the study will evaluate improvements in daily functioning, quality of life, motor abilities, and neurodevelopmental measures of the Cenegermin-bkbj intranasal formulation. CP is the most common motor disability in childhood, caused by injury or changes during early brain development. The most prevalent form, spastic CP, leads to muscle stiffness and difficulty with movement.2 “Cerebral palsy is a devastating disease, and for patients and families there are still no proven treatments beyond supportive care,” said Marcello Allegretti, Chief Scientific Officer at Dompé. “With our emerging intranasal NGF p

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom